The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits
Open accessAbstract
Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been identified or characterized. Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV glycoproteins from memory B cells of Lassa fever survivors from West Africa. One-half bind the GP2 fusion subunit, one-fourth recognize the GP1 receptor-binding subunit and the remaining fourth are specific for the assembled glycoprotein complex, requiring both GP1 and GP2 subunits for recognition. Notably, of the 16 mAbs that neutralize LASV, 13 require the assembled glycoprotein complex for binding, while the remaining 3 require GP1 only. Compared with non-neutralizing mAbs, neutralizing mAbs have higher binding affinities and greater divergence from germline progenitors. Some mAbs potently neutralize all four LASV lineages. These insights from LASV human mAb characterization will guide strategies for immunotherapeutic development and vaccine design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569
Proof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555
Cited by
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
Walker, L. M., & Burton, D. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.148 · Cited by 268
Chen, Y., Lu, S., Jia, H., Deng, Y., Zhou, J., Huang, B., Yu, Y., Lan, J., Wang, W., Lou, Y., et al. (2017) · Emerging Microbes & Infections · doi:10.1038/emi.2017.50 · Cited by 81
Vaisman-Mentesh, A., Rosenstein, S., Yavzori, M., Dror, Y., Fudim, E., Ungar, B., Kopylov, U., Picard, O., Kigel, A., Ben-Horin, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02921 · Cited by 54
Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation
Olmedillas, E., Rajamanickam, R. R., Avalos, R. D., Ana-Sosa-Batiz, F., Zyla, D., Zandonatti, M. A., Harkins, S. S., Shresta, S., Hastie, K. M., & Saphire, E. O. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116052 · Cited by 19
Self-citation
Metadata
- Authors
- Robinson, J. E., Hastie, K. M., Cross, R. W., Yenni, R. E., Elliott, D. H., Rouelle, J. A., Kannadka, C. B., Smira, A. A., Garry, C. E., Bradley, B. T., Yu, H., Shaffer, J. G., Boisen, M. L., Hartnett, J. N., Zandonatti, M. A., Rowland, M. M., Heinrich, M. L., Martínez-Sobrido, L., Cheng, B., de la Torre, J. C., Andersen, K. G., Goba, A., Momoh, M., Fullah, M., Gbakie, M., Kanneh, L., Koroma, V. J., Fonnie, R., Jalloh, S. C., Kargbo, B., Vandi, M. A., Gbetuwa, M., Ikponmwosa, O., Asogun, D. A., Okokhere, P. O., Follarin, O. A., Schieffelin, J. S., Pitts, K. R., Geisbert, J. B., Kulakoski, P. C., Wilson, R. B., Happi, C. T., Sabeti, P. C., Gevao, S. M., Khan, S. H., Grant, D. S., Geisbert, T. W., Saphire, E. O., Branco, L. M., & Garry, R. F.
- Venue
- Nature Communications
- Published
- 2016-05-10
- Volume
- 7
- Issue
- 1
- Pages
- 11544-11544
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2376309928
- Cited by
- 169
- References
- 2
- FWCI
- 13.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. https://app.cochat.ai/papers/10.1038/ncomms11544
- The paper
- Robinson, J. E., Hastie, K. M., Cross, R. W., Yenni, R. E., Elliott, D. H., Rouelle, J. A., Kannadka, C. B., Smira, A. A., Garry, C. E., Bradley, B. T., Yu, H., Shaffer, J. G., Boisen, M. L., Hartnett, J. N., Zandonatti, M. A., Rowland, M. M., Heinrich, M. L., Martínez-Sobrido, L., Cheng, B., . . . Garry, R. F. (2016). Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nature Communications. https://doi.org/10.1038/ncomms11544
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.